1.
Healthc (Amst)
; 9(4): 100581, 2021 Dec.
Article
in English
| MEDLINE | ID: covidwho-1401487
ABSTRACT
The interleukin-6 receptor antagonist tocilizumab became widely used early in the coronavirus disease 2019 (COVID-19) pandemic based on small observational studies that suggested clinical benefit in COVID-19 patients with a hyperinflammatory state. To inform our local treatment algorithms in the absence of randomized clinical trial results, we performed a rapid analysis of the first 11 hospitalized COVID-19 patients treated with tocilizumab at our academic medical center. We report their early clinical outcomes and describe the process by which we assembled a team of diverse trainees and stakeholders to extract, analyze, and disseminate data during a time of clinical uncertainty.
Subject(s)
COVID-19 Drug Treatment , Antibodies, Monoclonal, Humanized , Clinical Decision-Making , Cytokine Release Syndrome , Humans , Off-Label Use , Pandemics , SARS-CoV-2 , Treatment Outcome , Uncertainty
2.
Am J Respir Cell Mol Biol
; 63(4): 541-543, 2020 10.
Article
in English
| MEDLINE | ID: covidwho-694112